Medical Devices
All initial communications will be channeled through Flusso Capital to maintain a streamlined and effective investment process for all stakeholders.
Thank you for being a valued partner in our network.
MD248600
Robot-assisted and laparoscopic surgeries with its Surgical Precision Enhancement system. By integrating real-time AI, dynamic 3D mapping, and tissue recognition technology, SPE enhances surgical accuracy, reduces complications, and lowers healthcare costs.
Targeting a $10.1B global market, the system seamlessly integrates with existing surgical tools and is set for clinical testing in six leading hospitals. With patented technology and strong partnerships, the company seeks $3M to complete development, pursue FDA approval, and prepare for revenue generation within 24 months.
MD200982
This neurotechnology company is redefining chronic pain and neurological disorder treatment with its AI-driven, non-invasive neurofeedback solution. By offering an EEG-based headset for home use, it provides a scalable, drug-free alternative to opioid-dependent pain management, capturing a share of the $1.8 trillion global market for chronic and neurological care.
The company’s device is not only clinically validated and regulatory-approved but has also shown high early adoption rates, underscoring the strong demand for safe, accessible treatment options. Targeting expansion to other neurological conditions like anxiety and ADHD, they are raising $10 million to scale production, continue R&D, and extend product applications.
This funding round enables investors to enter at a critical juncture as the company scales to meet market needs, positions itself as a transformative leader in neurotech, and aligns with the global shift toward holistic, technology-driven healthcare solutions.
MD601024
Non-invasive, highly accurate breath analysis technology to detect lung cancer. Initially supported by the Gates Foundation, which funded its early development for tuberculosis detection. Their patented test detects cancer-specific biomarkers in exhaled breath, offering a faster, more affordable, and less invasive alternative to traditional methods like CT scans, which have a high (96%) false-positive rate.
With the sensitivity of 94% and specificity of 85%, this portable, easy-to-use system could revolutionize early detection of lung cancer, saving lives and reducing healthcare costs. Backed by clinical trials and strong intellectual property, the company is poised to disrupt the global cancer diagnostics market.
MD746398
Transforming traditional ultrasound into a powerful tool for early disease detection and remote monitoring. Using AI-driven image enhancement, their platform turns everyday ultrasounds into high-quality, actionable data that can be used by healthcare providers even outside hospital settings.
With a rapidly growing market for remote patient monitoring and strong partnerships with industry leaders like Roche and Mayo Clinic, they are poised to revolutionize healthcare by making advanced imaging accessible to all. Now seeking $5 million to scale their impact, they aim to bridge critical data gaps and improve patient outcomes worldwide.
MD824598
Portable brain imaging device, leveraging AI-enhanced electromagnetic tomography for rapid, on-site diagnosis of neurological emergencies like strokes and traumatic brain injuries.
Unlike traditional bulky and expensive imaging equipment, their solution is compact, affordable, and deployable across various settings—from hospitals and ambulances to remote communities—offering real-time, high-resolution imaging to improve patient outcomes and reduce costs.
With a rapidly growing market for portable medical devices and strong early traction, they are positioned to lead the next wave of innovation in brain healthcare, aiming to achieve widespread adoption and make advanced diagnostics accessible to all.